Neuromyelitis Optica (NMO) Antibodies; Anti-NMO; Anti-Aquaporin 4; AQP4 Antibody
Aquaporin 4 Antibodies (Anti-NMO), Serum
Test
Aliases/Synonyms
Method
Cell-Based Indirect Immunofluorescence
Report Includes
Aquaporin 4 Antibodies
Specimens
Serum
Clinical Utility
Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbor MOG antibodies. Patients very rarely harbour both antibodies.
Test Location
St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5
Test Version
24-Dec-2019
Specimen
Specimens
Serum
Sample Volume
1 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Separate as soon as possible. Store and send frozen.
Stability
Ambient | 6 hours |
---|---|
Refrigerated | 14 days |
Frozen | 60 days |
Test Version
24-Dec-2019
Performance / Interpretation
Method
Cell-Based Indirect Immunofluorescence
Turnaround Time
12 days
Results
Name | Units | Reference Range | Conversion Factor | |
---|---|---|---|---|
Aquaporin 4 Antibodies |
|
|||
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers
|
Test Location
St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5
Test Version
24-Dec-2019
Interface / Setup
HL7 Interface Codes
Order Code | Result Codes | Units |
---|---|---|
AQP4 S | 62782Anti Aquaporin 4 (NMO) |
Test Version
24-Dec-2019